SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

PVLA

Palvella Therapeutics Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor pipeline development timelines for QTORIN rapamycin and pitavastatin; assess future cash burn and potential for additional dilution. The capital raise extends runway but does not alter near-term clinical risk profile.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$132.61
T+0 close · Mar 2, 2026 · via day close
Latest settled
−11.33%
T+60 · $117.59
Vs SPY
−20.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $132.61entry
  2. T+1 · 9mo ago −0.83%α +0.09% · $131.51
  3. T+5 · 8mo ago +3.08%α +4.29% · $136.70
  4. T+20 · 8mo ago −16.55%α −8.61% · $110.66
  5. T+60 · 6mo ago −11.33%α −20.65% · $117.59
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics completed an upsized public offering of 1,840,000 shares at $125.00 per share, generating $230 million in gross proceeds. The capital will fund development of its QTORIN pipeline, including rapamycin and pitavastatin programs, and support general corporate purposes.

Key Financial Metrics

Deal Value
$230.0M

Key Facts

  • Palvella closed a public offering of 1,840,000 shares of common stock at $125.00 per share.
  • The offering included full exercise of the underwriters' option to purchase 240,000 additional shares.
  • Gross proceeds totaled $230 million before underwriting discounts and expenses.
  • Proceeds will be used to advance QTORIN rapamycin and QTORIN pitavastatin programs, and for working capital and R&D.
  • The offering was conducted under a shelf registration (Form S-3) declared effective January 29, 2026.

Financial Impact

$230 million in gross proceeds; dilution estimated at approximately 10-12% based on $1.6B market cap

dilutioncashequity

Risk Factors

  • Dilution to existing shareholders from issuance of new shares
  • No assurance of clinical success for QTORIN pipeline candidates
  • Forward-looking statements about use of proceeds subject to execution risk

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247266

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026